Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Methenamine Hippurate Tablets Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The methenamine hippurate tablets market size has shown robust expansion in recent years. Its valuation is set to rise from $10.11 billion in 2025 to $10.86 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. Historically, this market growth can be ascribed to factors like limited awareness regarding recurrent UTI prevention, constrained availability of specialized urology care, a low rate of adoption for antimicrobial tablets, dependence on hospital-centric treatment, and conventional packaging styles.
The methenamine hippurate tablets market is projected to experience robust expansion over the coming years, with its size anticipated to reach $14.49 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.5%. This expansion during the forecast period is primarily attributed to factors such as the increasing incidence of urinary tract infections, a rising demand for outpatient and homecare treatment options, advancements in tablet formulation technology, the growing adoption of personalized medicine, and the expansion of online pharmacy channels. Key trends expected throughout this timeframe encompass the escalating prevalence of recurrent UTIs, an increase in the geriatric population, a growing preference for oral antimicrobial therapies, the broadening of home , and the emergence of personalized medication regimens.
Get A Free Sample Report With In-Depth Market Insights:
Methenamine Hippurate Tablets Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The methenamine hippurate tablets market is anticipated to expand due to an increase in urinary tract infection (UTI) cases. UTIs are prevalent conditions resulting from bacteria entering the urinary tract, typically via the urethra from the skin or rectum. Methenamine hippurate tablets serve to either prevent or manage recurrent urinary tract infections caused by particular bacteria. As an illustration, the National Health Service, a UK-based government department, reported in October 2023 that during the 2022-23 period, 147,285 admissions had urinary tract infections (UTIs) as the primary diagnosis. Among these, 56% (82,392) involved individuals aged 65 and older, with the 80-84 age group experiencing the highest number of admissions, totaling 17,280 admissions. Consequently, the increasing incidence of urinary tract infections is propelling the growth of the methenamine hippurate market.
Methenamine Hippurate Tablets Market Segment Landscape: Which Areas Lead Development?
The methenamine hippurate tablets market covered in this report is segmented –
1) By Type: 20 Tablets Or Bottle, 6 Tablets Or Bottle
2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
3) By Application: Uncomplicated UTIs, Healthcare-associated UTIs
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By 20 Tablets per Bottle: Standard Packaging, Bulk Packaging Options
2) By 6 Tablets per Bottle: Standard Packaging, Sample Or Trial Packaging
Methenamine Hippurate Tablets Market Innovation Trends Shaping Future Development
Leading companies within the methenamine hippurate tablets market are forming partnerships to boost their market profitability. A strategic collaboration signifies an intentional alliance between entities aimed at achieving common goals through synchronized efforts, utilizing each other’s distinct strengths and assets. For example, in May 2023, EQL Pharma AB, a pharmaceutical company based in Sweden that offers methenamine hippurate tablets, joined forces with Dr. Pfleger Arzneimittel GmbH. This collaboration allows EQL Pharma AB to plan the launch of Methenamine Hippurate under an EQL-registered brand within the upcoming two years, incorporating standard license fees, specific regulatory and reimbursement milestones, and a supply price dependent on volume, contingent upon regulatory approval. Dr. Pfleger Arzneimittel GmbH is a pharmaceutical firm located in Germany.
Methenamine Hippurate Tablets Market Industry Leaders And Competitive Landscape
Major companies operating in the methenamine hippurate tablets market are Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH, Mylan Laboratories Ltd.
View The Full Methenamine Hippurate Tablets Market Report:
Methenamine Hippurate Tablets Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the methenamine hippurate tablets market in 2025. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
